Will the Phase 2 trial "Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors" reach primary completion on or before Dec 30, 2026?

Resolves Yes if ClinicalTrials.gov record NCT05768464 (The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School) shows an actual primary completion date on or before Dec 30, 2026. Registered date at generation: Dec 30, 2026.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Dec 30, 2026, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.